Titre : Lactoyl glutathione lyase

Lactoyl glutathione lyase : Questions médicales fréquentes

Termes MeSH sélectionnés :

Prostatic Neoplasms
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Lactoyl glutathione lyase : Questions médicales les plus fréquentes", "headline": "Lactoyl glutathione lyase : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Lactoyl glutathione lyase : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-19", "dateModified": "2025-02-13", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Lactoyl glutathione lyase" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Carbon-sulfur lyases", "url": "https://questionsmedicales.fr/mesh/D013437", "about": { "@type": "MedicalCondition", "name": "Carbon-sulfur lyases", "code": { "@type": "MedicalCode", "code": "D013437", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.520.300" } } }, "about": { "@type": "MedicalCondition", "name": "Lactoyl glutathione lyase", "alternateName": "Lactoylglutathione Lyase", "code": { "@type": "MedicalCode", "code": "D007791", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Yu-Zhong Zhang", "url": "https://questionsmedicales.fr/author/Yu-Zhong%20Zhang", "affiliation": { "@type": "Organization", "name": "College of Marine Life Sciences, Frontiers Science Center for Deep Ocean Multispheres and Earth System, Ocean University of China, Qingdao 266003, China." } }, { "@type": "Person", "name": "Julie D Saba", "url": "https://questionsmedicales.fr/author/Julie%20D%20Saba", "affiliation": { "@type": "Organization", "name": "Children's Hospital Oakland Research Institute, University of California, San Francisco Benioff Children's Hospital Oakland, Oakland, CA 94609 jsaba@chori.org." } }, { "@type": "Person", "name": "Lidia de Bari", "url": "https://questionsmedicales.fr/author/Lidia%20de%20Bari", "affiliation": { "@type": "Organization", "name": "Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies-CNR, Via G. Amendola 122/O, 70126 Bari, Italy." } }, { "@type": "Person", "name": "Marissa N Trujillo", "url": "https://questionsmedicales.fr/author/Marissa%20N%20Trujillo", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Erin Q Jennings", "url": "https://questionsmedicales.fr/author/Erin%20Q%20Jennings", "affiliation": { "@type": "Organization", "name": "" } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Epidemiology, Pattern, and Survival of Multiple Primary Malignant Neoplasms in Southeast Iran: Results of Kerman Population-Based Cancer Registry 2014-2020.", "datePublished": "2024-07-01", "url": "https://questionsmedicales.fr/article/39068556", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.31557/APJCP.2024.25.7.2257" } }, { "@type": "ScholarlyArticle", "name": "Gastric epithelial neoplasm of fundic-gland mucosa lineage: representative of the low atypia differentiated gastric tumor and Ki67 may help in their identification.", "datePublished": "2024-05-30", "url": "https://questionsmedicales.fr/article/38873175", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/pore.2024.1611734" } }, { "@type": "ScholarlyArticle", "name": "Pancreatic volume and endocrine function changes following pancreaticoduodenectomy for peri-ampullary neoplasms: A retrospective single-center study utilizing pancreas volumetry.", "datePublished": "2024-04-23", "url": "https://questionsmedicales.fr/article/38650471", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.14701/ahbps.24-004" } }, { "@type": "ScholarlyArticle", "name": "SOX11+ Large B-cell Neoplasms: Cyclin D1-Negative Blastoid/Pleomorphic Mantle Cell Lymphoma or Large B-cell Lymphoma?", "datePublished": "2023-12-15", "url": "https://questionsmedicales.fr/article/38104893", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.modpat.2023.100405" } }, { "@type": "ScholarlyArticle", "name": "Efficacy of venetoclax combined with decitabine conditioning regimen for allogeneic hematopoietic stem cell transplantation in high-risk and elderly patients with myeloid neoplasms.", "datePublished": "2023-10-25", "url": "https://questionsmedicales.fr/article/37878011", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00277-023-05500-2" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Enzymes et coenzymes", "item": "https://questionsmedicales.fr/mesh/D045762" }, { "@type": "ListItem", "position": 3, "name": "Enzymes", "item": "https://questionsmedicales.fr/mesh/D004798" }, { "@type": "ListItem", "position": 4, "name": "Lyases", "item": "https://questionsmedicales.fr/mesh/D008190" }, { "@type": "ListItem", "position": 5, "name": "Carbon-sulfur lyases", "item": "https://questionsmedicales.fr/mesh/D013437" }, { "@type": "ListItem", "position": 6, "name": "Lactoyl glutathione lyase", "item": "https://questionsmedicales.fr/mesh/D007791" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Lactoyl glutathione lyase - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Lactoyl glutathione lyase", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-05", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Lactoyl glutathione lyase", "description": "Comment diagnostiquer une déficience en lactoyl glutathione lyase ?\nQuels tests sont utilisés pour évaluer l'activité de cette enzyme ?\nQuels symptômes peuvent indiquer un problème avec cette enzyme ?\nY a-t-il des biomarqueurs associés à cette enzyme ?\nPeut-on utiliser l'imagerie pour diagnostiquer des troubles liés à cette enzyme ?", "url": "https://questionsmedicales.fr/mesh/D007791?mesh_terms=Prostatic+Neoplasms&page=1000#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Lactoyl glutathione lyase", "description": "Quels sont les symptômes d'une déficience en lactoyl glutathione lyase ?\nLa déficience peut-elle causer des problèmes cutanés ?\nY a-t-il des symptômes digestifs associés ?\nLes symptômes varient-ils selon l'âge ?\nPeut-on observer des symptômes psychologiques ?", "url": "https://questionsmedicales.fr/mesh/D007791?mesh_terms=Prostatic+Neoplasms&page=1000#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Lactoyl glutathione lyase", "description": "Comment prévenir les complications liées à cette enzyme ?\nY a-t-il des tests de dépistage recommandés ?\nLes antioxydants peuvent-ils prévenir des problèmes ?\nEst-il important de gérer le stress ?\nLes vaccinations sont-elles importantes ?", "url": "https://questionsmedicales.fr/mesh/D007791?mesh_terms=Prostatic+Neoplasms&page=1000#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Lactoyl glutathione lyase", "description": "Quels traitements sont disponibles pour la déficience en lactoyl glutathione lyase ?\nLa thérapie génique est-elle une option ?\nDes changements alimentaires peuvent-ils aider ?\nY a-t-il des médicaments spécifiques à éviter ?\nLes traitements sont-ils personnalisés ?", "url": "https://questionsmedicales.fr/mesh/D007791?mesh_terms=Prostatic+Neoplasms&page=1000#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Lactoyl glutathione lyase", "description": "Quelles complications peuvent survenir avec cette déficience ?\nLa déficience peut-elle affecter le système immunitaire ?\nY a-t-il des risques de maladies chroniques ?\nLes complications sont-elles réversibles ?\nComment surveiller les complications potentielles ?", "url": "https://questionsmedicales.fr/mesh/D007791?mesh_terms=Prostatic+Neoplasms&page=1000#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Lactoyl glutathione lyase", "description": "Quels sont les facteurs de risque pour cette déficience ?\nL'âge joue-t-il un rôle dans le risque ?\nY a-t-il des maladies associées à ce risque ?\nLe mode de vie influence-t-il le risque ?\nLes facteurs environnementaux sont-ils significatifs ?", "url": "https://questionsmedicales.fr/mesh/D007791?mesh_terms=Prostatic+Neoplasms&page=1000#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une déficience en lactoyl glutathione lyase ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests enzymatiques et des analyses génétiques peuvent confirmer la déficience." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer l'activité de cette enzyme ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests biochimiques mesurant l'activité enzymatique dans des échantillons biologiques." } }, { "@type": "Question", "name": "Quels symptômes peuvent indiquer un problème avec cette enzyme ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes de stress oxydatif, comme la fatigue ou des troubles neurologiques." } }, { "@type": "Question", "name": "Y a-t-il des biomarqueurs associés à cette enzyme ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des niveaux anormaux de glutathion et de lactate peuvent être des biomarqueurs." } }, { "@type": "Question", "name": "Peut-on utiliser l'imagerie pour diagnostiquer des troubles liés à cette enzyme ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'imagerie n'est pas spécifique, mais peut aider à évaluer des complications associées." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une déficience en lactoyl glutathione lyase ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Fatigue, troubles neurologiques, et susceptibilité accrue aux infections." } }, { "@type": "Question", "name": "La déficience peut-elle causer des problèmes cutanés ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des éruptions cutanées et une sensibilité accrue peuvent survenir." } }, { "@type": "Question", "name": "Y a-t-il des symptômes digestifs associés ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des troubles digestifs comme des nausées peuvent être présents." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon l'âge ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent être plus prononcés chez les jeunes enfants." } }, { "@type": "Question", "name": "Peut-on observer des symptômes psychologiques ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des troubles de l'humeur et de l'anxiété peuvent être liés à cette déficience." } }, { "@type": "Question", "name": "Comment prévenir les complications liées à cette enzyme ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Un mode de vie sain et une alimentation équilibrée peuvent aider à prévenir les complications." } }, { "@type": "Question", "name": "Y a-t-il des tests de dépistage recommandés ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de dépistage génétique peuvent être recommandés pour les familles à risque." } }, { "@type": "Question", "name": "Les antioxydants peuvent-ils prévenir des problèmes ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une consommation adéquate d'antioxydants peut réduire le stress oxydatif." } }, { "@type": "Question", "name": "Est-il important de gérer le stress ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la gestion du stress est cruciale pour maintenir une bonne santé cellulaire." } }, { "@type": "Question", "name": "Les vaccinations sont-elles importantes ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les vaccinations peuvent aider à prévenir les infections chez les personnes à risque." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour la déficience en lactoyl glutathione lyase ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des suppléments de glutathion et des antioxydants peuvent être recommandés." } }, { "@type": "Question", "name": "La thérapie génique est-elle une option ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "La thérapie génique est en recherche, mais pas encore largement disponible." } }, { "@type": "Question", "name": "Des changements alimentaires peuvent-ils aider ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation riche en antioxydants peut soutenir la santé cellulaire." } }, { "@type": "Question", "name": "Y a-t-il des médicaments spécifiques à éviter ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Certains médicaments oxydants doivent être évités pour réduire le stress oxydatif." } }, { "@type": "Question", "name": "Les traitements sont-ils personnalisés ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements peuvent être adaptés selon la gravité des symptômes." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec cette déficience ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications comme des infections récurrentes et des troubles neurologiques peuvent survenir." } }, { "@type": "Question", "name": "La déficience peut-elle affecter le système immunitaire ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut affaiblir le système immunitaire, augmentant le risque d'infections." } }, { "@type": "Question", "name": "Y a-t-il des risques de maladies chroniques ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un stress oxydatif accru peut contribuer à des maladies chroniques." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes." } }, { "@type": "Question", "name": "Comment surveiller les complications potentielles ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Des suivis réguliers avec des professionnels de santé sont essentiels pour surveiller les complications." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour cette déficience ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Des antécédents familiaux et des expositions environnementales peuvent augmenter le risque." } }, { "@type": "Question", "name": "L'âge joue-t-il un rôle dans le risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les jeunes enfants sont plus susceptibles de présenter des déficiences enzymatiques." } }, { "@type": "Question", "name": "Y a-t-il des maladies associées à ce risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Certaines maladies métaboliques peuvent être liées à un risque accru de déficience." } }, { "@type": "Question", "name": "Le mode de vie influence-t-il le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie malsain peut augmenter le risque de complications liées à cette enzyme." } }, { "@type": "Question", "name": "Les facteurs environnementaux sont-ils significatifs ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à des toxines environnementales peut augmenter le risque de déficience." } } ] } ] }

Sources (10000 au total)

Epidemiology, Pattern, and Survival of Multiple Primary Malignant Neoplasms in Southeast Iran: Results of Kerman Population-Based Cancer Registry 2014-2020.

Cancer survivors may experience a subsequent primary cancer that affects their survival and quality of life. This study aimed to investigate the epidemiology of multiple primary malignant neoplasms (M... In this retrospective cohort study, all patients who had been diagnosed with primary cancers and registered with the Kerman Cancer Registry Program (KPBCR) during 2014-2020 were included. MPMNs were d... Of 26,315 patients registered with a primary cancer diagnosis, 492 (1.86%) developed subsequent primary cancers. The most common type of secondary cancer was skin and mucosa (n=131, 26.63%) followed b... Both patients and physicians should be taught about the importance of prevention and the provision of care and screening services among cancer survivors. Studying the epidemiology, susceptibility, and...

Gastric epithelial neoplasm of fundic-gland mucosa lineage: representative of the low atypia differentiated gastric tumor and Ki67 may help in their identification.

Gastric epithelial neoplasm of the fundic-gland mucosa lineages (GEN-FGMLs) are rare forms of gastric tumors that encompass oxyntic gland adenoma (OGA), gastric adenocarcinoma of the fundic-gland type... 37 cases diagnosed with GEN-FGMLs were included in this study. H&E-stained slides were reviewed and clinicopathological parameters were recorded. Immunohistochemical staining was conducted for MUC2, M... The patients' ages ranged from 42 to 79 years, with a median age of 60. 17 were male and 20 were female. Morphologically, 19 OGAs, 16 GA-FGs, and two GA-FGMs were identified. Histopathological similar... GEN-FGMLs are group of well-differentiated gastric tumors with favourable biological behaviours, low cellular atypia, and low proliferation. Immunohistochemistry is critical for confirming diagnosis. ...

Pancreatic volume and endocrine function changes following pancreaticoduodenectomy for peri-ampullary neoplasms: A retrospective single-center study utilizing pancreas volumetry.

We evaluated long-term pancreatic functional outcomes, including pancreatic volumetry after pancreaticoduodenectomy (PD) for peri-ampullary neoplasm.... We retrospectively reviewed 353 patients with a 12-month follow-up who underwent elective pancreaticoduodenectomies for peri-ampullary neoplasms at a single university hospital between January 2011 an... The mean age was 65.4 years, and the sex ratio was 1.38. The patients with prediagnosed diabetes mellitus (DM) comprised 31.4%. The peri-ampullary neoplasm origins were: the pancreas (49.0%), common b... Following PD for peri-ampullary neoplasms, pancreatic endocrine functions and volumes continued to decrease for a minimum of 12 months. The current study did not identify any causal relationship betwe...

Efficacy of venetoclax combined with decitabine conditioning regimen for allogeneic hematopoietic stem cell transplantation in high-risk and elderly patients with myeloid neoplasms.

This prospective clinical investigation focused on the addition of venetoclax and decitabine to myeloablative conditioning regimens, targeting high-risk and elderly individuals undergoing allogeneic h...

Comparability of JAK2 p.V617F allele burden in peripheral blood and that in bone marrow in patients with suspected myeloproliferative neoplasms: a single-center prospective study.

To detect JAK2 p.V617F and measure allele burden in peripheral blood (PB) and bone marrow (BM) aspirates in patients with suspected myeloproliferative neoplasms (MPNs).... Patients with suspected MPNs were prospectively enrolled between August 2017 and May 2019, and their PB and BM were collected during the same period. Quantitative fluorescence polymerase chain reactio... Among 54 patients with suspected MPNs, 43 of them were eligible for analysis. The JAK2 p.V617F in PB had the same sensitivity and specificity as BM (all P>0.05). The Chi-square test suggested that the... PB could be used as an alternative to BM for JAK2 p.V617F measurement in patients with suspected MPNs....

Challenges and positive impact of rare cancer caregiving: A mixed-methods study of caregivers of patients with Erdheim-Chester disease and other histiocytic neoplasms.

The importance of deriving benefit and meaning has been identified among cancer caregivers, but this has yet to be examined in the context of rare cancers. We sought to characterize unmet needs and ex... Caregivers of patients with ECD and other HN completed quantitative surveys. Linear univariable regression modeling examined associations between unmet needs, social and family support, and intoleranc... Of caregivers (... Rare cancer caregivers report numerous unmet information and support needs, needs that arise from disease rarity itself and which are associated with diminished capacity for deriving benefit and meani... NIH P30 CA008748 (PI: Craig Thompson, MD), NIH T32 CA009461 (H.M.; PI: Jamie Ostroff, PhD), Frame Family Fund (E.L.D.), Applebaum Foundation (E.L.D.)....

Real-world costs and dynamics of surveillance in patients who underwent surgery for low-risk branch duct intraductal papillary mucinous neoplasms.

Surveillance costs and appropriateness of surgery of "low-risk" BD-IPMNs are relevant issues. In this study we evaluated the rate of correct indication for pancreatectomy defined as high grade dysplas...